[HTML][HTML] Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
JM Lee, A Ahn, EJ Min, SE Lee, M Kim, Y Kim - Blood Cancer Journal, 2023 - nature.com
Dear Editor, Myelofibrosis (MF) is the most severe form of myeloproliferative neoplasm
(MPN). Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only known …
(MPN). Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only known …
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
H Alchalby, A Badbaran, T Zabelina… - Blood, The Journal …, 2010 - ashpublications.org
Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become
a reasonable treatment option for patients with advanced myelofibrosis. The role of …
a reasonable treatment option for patients with advanced myelofibrosis. The role of …
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
N Kröger, A Badbaran, E Holler, J Hahn, G Kobbe… - Blood, 2007 - ashpublications.org
Abstract The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and
might be a reliable marker to monitor residual disease after allogeneic stem cell …
might be a reliable marker to monitor residual disease after allogeneic stem cell …
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis
M Ditschkowski, AH Elmaagacli, R Trenschel… - Biology of Blood and …, 2006 - tctjournal.org
The occurrence of an acquired single-point mutation (Val617Phe) of the tyrosine kinase
gene JAK2 in a large proportion of patients with polycythemia vera, essential …
gene JAK2 in a large proportion of patients with polycythemia vera, essential …
Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms
K Haslam, KM Molloy, E Conneally… - Clinical Chemistry and …, 2014 - degruyter.com
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic diseases
characterized by bone marrow proliferation of one or more of the myeloid cell lineages with …
characterized by bone marrow proliferation of one or more of the myeloid cell lineages with …
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
MRM de Conchon, JL Costa, MMY Novaes… - International journal of …, 2008 - Springer
Myelofibrosis and chronic myeloid leukemia (CML) are myeloproliferative disorders (MPD)
of hematopoietic stem cell and characterized by clonal neoplastic proliferation of one or …
of hematopoietic stem cell and characterized by clonal neoplastic proliferation of one or …
JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes
Abstract JAK2 V617F is the most common driver mutation in primary or secondary
myelofibrosis for which allogeneic hematopoietic cell transplantation (HCT) is the only …
myelofibrosis for which allogeneic hematopoietic cell transplantation (HCT) is the only …
JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell …
N Kröger, H Alchalby, E Klyuchnikov… - Blood, The Journal …, 2009 - ashpublications.org
With great interest we have read the letter by Terriou and coworkers, who have performed
an extensive survey of CEBPA CpG promoter hypermethylation in T-ALL as well as in a …
an extensive survey of CEBPA CpG promoter hypermethylation in T-ALL as well as in a …
[HTML][HTML] ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
YH Wang, CC Lin, SH Lee, CH Tsai, SJ Wu… - Blood Cancer …, 2020 - nature.com
Dear Editor, JAK2V617F is the most common driver mutation identified in primary
myelofibrosis (PMF), followed by CALR and MPL mutations. In addition to the International …
myelofibrosis (PMF), followed by CALR and MPL mutations. In addition to the International …
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic …
M Koren-Michowitz, A Shimoni, A Vivante… - Leukemia Research, 2008 - Elsevier
JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a
quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility …
quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility …